Zobrazeno 31 - 40
of 382
pro vyhledávání: '"C. Kent Osborne"'
Autor:
Powel H. Brown, Ching C. Lau, Gordon B. Mills, Jenny C. Chang, Susan G. Hilsenbeck, C. Kent Osborne, Michelle I Savage, Suzanne A.W. Fuqua, Alejandro Contreras, Kyle R. Covington, Graham M. Poage, Anna Tsimelzon, Matthew D. Burstein
Table S11. 80 Gene Signature for NMF Cluster 1 (LAR). Table S12. 80 Gene Signature for NMF Cluster 2 (MES). Table S13. 80 Gene Signature for NMF Cluster 3 (BLIS). Table S14. 80 Gene Signature for NMF Cluster 4 (BLIA). Table S15. Assignment of Discove
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ffafa23da4c3e339f1606983ec09878
https://doi.org/10.1158/1078-0432.22460255
https://doi.org/10.1158/1078-0432.22460255
Autor:
Powel H. Brown, Ching C. Lau, Gordon B. Mills, Jenny C. Chang, Susan G. Hilsenbeck, C. Kent Osborne, Michelle I Savage, Suzanne A.W. Fuqua, Alejandro Contreras, Kyle R. Covington, Graham M. Poage, Anna Tsimelzon, Matthew D. Burstein
Figure S1. Full clustering metrics in support of a 4 cluster model in the discovery set with membership as defined by TNBCType. Figure S2. Full clustering metrics in support of a 4 cluster model in the validation set with membership as defined by the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e357903a4f9213376634fb0e17ee785e
https://doi.org/10.1158/1078-0432.22460264.v1
https://doi.org/10.1158/1078-0432.22460264.v1
Autor:
Stephen Johnston, Judith M. Bliss, Claire Swift, Nick Turner, Chris Holcombe, Sophie Perry, Maggie Cheang, Vera Martins, Andrew Dodson, Shannon Puhalla, Melanie Finnigan, Samuel A. Jacobs, Yuan Liu, Katherine Pogue-Geile, C. Kent Osborne, Mothaffar F. Rimawi, Lucy Kilburn, Mitch Dowsett
Purpose:To determine (i) the relationship between candidate biomarkers of the antiproliferative (Ki67) response to letrozole and palbociclib alone and combined in ER+/HER2− breast cancer; and (ii) the pharmacodynamic effect of the agents on the bio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2279285765c81c0e79596b56399a3d4e
https://doi.org/10.1158/1078-0432.c.6531375.v1
https://doi.org/10.1158/1078-0432.c.6531375.v1
Autor:
Rachel Schiff, C. Kent Osborne, Rinath Jeselsohn, Valerie M. Jansen, Mothaffar F. Rimawi, Dennis J. Slamon, Sara A. Hurvitz, Ben H. Park, Jorge S. Reis-Filho, Britta Weigelt, David N. Brown, Pier Selenica, Joshua Donaldson, Jiangang Liu, Lacey M. Litchfield, Luca Malorni, Cristina Guarducci, Ilenia Migliaccio, Matteo Benelli, Susan G. Hilsenbeck, Tao Wang, Vidyalakshmi Sethunath, Lanfang Qin, Sarmistha Nanda, Jamunarani Veeraraghavan, Resel Pereira, Agostina Nardone, Maria Letizia Cataldo, Xiaoyong Fu, Carmine De Angelis
Supplementary Figure S1. ER, PR, and HER2 mRNA and protein levels across endocrine-sensitive (parental) and endocrine-resistant BC cell lines. Supplementary Figure S2. Reduced sensitivity to CDK4/6 inhibition is associated with IFN-signaling in ER+ a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ca189794e5917e4f6ef6e2b541b4485
https://doi.org/10.1158/1078-0432.22481033.v1
https://doi.org/10.1158/1078-0432.22481033.v1
Autor:
Powel H. Brown, Ching C. Lau, Gordon B. Mills, Jenny C. Chang, Susan G. Hilsenbeck, C. Kent Osborne, Michelle I Savage, Suzanne A.W. Fuqua, Alejandro Contreras, Kyle R. Covington, Graham M. Poage, Anna Tsimelzon, Matthew D. Burstein
Purpose: Genomic profiling studies suggest that triple-negative breast cancer (TNBC) is a heterogeneous disease. In this study, we sought to define TNBC subtypes and identify subtype-specific markers and targets.Experimental Design: RNA and DNA profi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::58c8adb9df81b92d9de543197637e176
https://doi.org/10.1158/1078-0432.c.6524435.v1
https://doi.org/10.1158/1078-0432.c.6524435.v1
Autor:
C. Kent Osborne, Susan G. Hilsenbeck, Rachel Schiff, Carolina Gutierrez, Carmine De Angelis, Jamunarani Veeraraghavan, Anne Pavlick, Sao Jiralerspong, Julie R. Nangia, Matthew P. Goetz, Ian Krop, Anna M. Storniolo, Rita Nanda, Antonio C. Wolff, Andres Forero, Brent N. Rexer, Tao Wang, Polly Niravath, Mothaffar F. Rimawi
Characteristics of TBCRC023 Patients with disease progression
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13100d67d3c3c165e7636e12fcd8a7bc
https://doi.org/10.1158/1078-0432.22472811
https://doi.org/10.1158/1078-0432.22472811
Autor:
Rachel Schiff, Mothaffar F. Rimawi, C. Kent Osborne, Jenny C. Chang, Gary C. Chamness, Meghana V. Trivedi, Anne C. Pavlick, Sara Lopez-Tarruella, Joe W. Gray, Laura M. Heiser, Nicholas J. Wang, Carmine De Angelis, Susan G. Hilsenbeck, Tao Wang, Carolina Gutierrez, Alejandro Contreras, Sufeng Mao, Sabrina Herrera, Agostina Nardone, Xiaoyong Fu, Yen-Chao Wang, Huizhong Hu, Mario Giuliano
Supplementary Figure 2. ER expression changes upon neoadjuvant treatment with trastuzumab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37b38ed6a099216efbf2e1288834c85f
https://doi.org/10.1158/1078-0432.22456521.v1
https://doi.org/10.1158/1078-0432.22456521.v1
Autor:
Rachel Schiff, Mothaffar F. Rimawi, C. Kent Osborne, Jenny C. Chang, Gary C. Chamness, Meghana V. Trivedi, Anne C. Pavlick, Sara Lopez-Tarruella, Joe W. Gray, Laura M. Heiser, Nicholas J. Wang, Carmine De Angelis, Susan G. Hilsenbeck, Tao Wang, Carolina Gutierrez, Alejandro Contreras, Sufeng Mao, Sabrina Herrera, Agostina Nardone, Xiaoyong Fu, Yen-Chao Wang, Huizhong Hu, Mario Giuliano
Purpose: To investigate the direct effect and therapeutic consequences of epidermal growth factor receptor 2 (HER2)-targeting therapy on expression of estrogen receptor (ER) and Bcl2 in preclinical models and clinical tumor samples.Experimental desig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47e0587fb0456056a2d9cbd81adb8b39
https://doi.org/10.1158/1078-0432.c.6523335
https://doi.org/10.1158/1078-0432.c.6523335
Autor:
C. Kent Osborne, Susan G. Hilsenbeck, Rachel Schiff, Carolina Gutierrez, Carmine De Angelis, Jamunarani Veeraraghavan, Anne Pavlick, Sao Jiralerspong, Julie R. Nangia, Matthew P. Goetz, Ian Krop, Anna M. Storniolo, Rita Nanda, Antonio C. Wolff, Andres Forero, Brent N. Rexer, Tao Wang, Polly Niravath, Mothaffar F. Rimawi
Purpose:Prior neoadjuvant trials with 12 weeks of dual anti-HER2 therapy without chemotherapy demonstrated a meaningful pathologic complete response (pCR) in patients with HER2-positive breast cancer. In this trial, we sought to determine whether lon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::889a51e15e833165a8ee8c17165f33f2
https://doi.org/10.1158/1078-0432.c.6528333
https://doi.org/10.1158/1078-0432.c.6528333
Autor:
Rachel Schiff, C. Kent Osborne, Jorge S. Reis-Filho, Britta Weigelt, Joe W. Gray, Mothaffar F. Rimawi, Susan G. Hilsenbeck, Chad A. Shaw, Ben H. Park, Gary C. Chamness, Felipe C. Geyer, Chandandeep Nagi, Carolina Gutierrez, Kenneth L. Scott, Daniel J. Zabransky, Ian Waters, Mahitha Rajendran, Tamika Mitchell, Martin Shea, Sarmistha Nanda, Tao Wang, Alexander Renwick, Edward S. Chen, Charlotte K.Y. Ng, Nicholas Wang, Laura M. Heiser, Vidyalakshmi Sethunath, Jamunarani Veeraraghavan, Lanfang Qin, Huizhong Hu, Agostina Nardone, Kathleen A. Burke, Carmine De Angelis, Xiaowei Xu
Purpose: Resistance to anti-HER2 therapies in HER2+ breast cancer can occur through activation of alternative survival pathways or reactivation of the HER signaling network. Here we employed BT474 parental and treatment-resistant cell line models to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e201b57c505d629e55aa1001b1f5bfb
https://doi.org/10.1158/1078-0432.c.6526164.v1
https://doi.org/10.1158/1078-0432.c.6526164.v1